Mannkind (MNKD) Stock: Buy, Sell, or Hold?
MNKD - Mannkind Corporation
$3.76
-0.19 (-4.81%)
âŧ
5d:
+12.57%
30d:
-6.93%
90d:
-11.94%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When MNKD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: MNKD is fairly priced but lacks strong directional signals. At 7.3% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: MNKD is fairly priced but lacks strong directional signals. At 7.3% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: MNKD is currently trading at $3.76, which is considered fair relative to its 30-day fair value range of $3.49 to $4.05. From a valuation perspective, the stock is trading at a premium (Forward PE: 31.0) compared to its historical average (25.1). At these levels, the market is pricing in 7.3% annual earnings growth.
Technical Outlook: Technically, MNKD is in a uptrend. Immediate support is located at $3.17, while resistance sits at $4.22. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: The stock scores a mixed 51/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.97 (+101.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MNKD is in a uptrend. Immediate support is located at $3.17, while resistance sits at $4.22. Short-term momentum is weak, with the stock down 4.8% recently.
Market Sentiment: The stock scores a mixed 51/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.97 (+101.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.49 -
$4.05
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.0%
Protect Your Profits
Holding MNKD? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (51/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.8%)
- BULLISH: Trading 101.7% below Wall St target ($7.97)
- BULLISH: Expecting earnings turnaround to 7.3% growth with 42.9% revenue growth
- WARNING: Composite score 50/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.49 -
$4.05
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$3.17
Resistance Level
$4.23
Current Trend
Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
30.98
Wall Street Target
$7.97
(+101.7%)
Revenue Growth (YoY)
42.9%
Earnings Growth (YoY)
-34.9%
Profit Margin
-11.1%
Valuation Premium vs History
+7.3% premium
PE vs Historical
31.0 vs 25.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+7.3%
(market-implied from PE analysis)
1-Year Target
$4.24
(+7%)
2-Year Target
$4.55
(+15%)
3-Year Target
$4.88
(+24%)
3-Yr Target (if PE normalizes)
(PE: 31â25)
PE COMPRESSION
$3.95
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 31.0, Growth: 325.0%)
$13.33
(+238%)
Base:
(SPY PE: 20.4, Growth: 325.0%)
$8.78
(+122%)
Bear:
(PE: 17.3, Growth: 325.0%)
$7.46
(+89%)
Share & Embed Analysis
Last updated: October 02, 2026 3:34 PM ET
Data refreshes hourly during market hours. Next update: 4:34 PM
Data refreshes hourly during market hours. Next update: 4:34 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MNKD showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical âĻ |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 56 HOLD |
Advanced MNKD Option Strategies
Professional options setups generated by AI based on today's MNKD price and gamma walls.
